Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Study for Evaluation of the Safety and Efficacy of Humacyte's Human Acellular Vascular Graft as an Above-Knee Femoro-Popliteal Bypass Graft in Patients With Peripheral Arterial Disease

Next Previous
X
Search
Trial Profile

A Pilot Study for Evaluation of the Safety and Efficacy of Humacyte's Human Acellular Vascular Graft as an Above-Knee Femoro-Popliteal Bypass Graft in Patients With Peripheral Arterial Disease

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Human acellular vessel-Humacyte (Primary)
  • Indications Peripheral arterial disorders
  • Focus Adverse reactions
  • Sponsors Humacyte

    • Most Recent Events

    • 24 Jan 2023 According to Humacyte media release, the company announced the publication of 6-year outcomes of a phase II study of human-tissue engineered blood vessels for peripheral arterial bypass, in the Journal of Vascular Surgery - Vasular Science. The publication describes the long-term analysis of this study.
    • 17 Aug 2022 Planned End Date changed from 1 Jun 2024 to 1 May 2026.
    • 11 Oct 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top